Entero Healthcare Solutions Limited has announced the successful merger of its subsidiaries, Chethana Pharma Distributors Private Limited and CPD Pharma Private Limited, into Rada Medisolutions Private Limited. This strategic consolidation, sanctioned by the Ministry of Corporate Affairs, aims to simplify the group’s corporate structure and enhance operational efficiency. The amalgamation is deemed effective from April 15, 2025, and marks a significant step in optimizing resource utilization across the organization.
Strategic Business Consolidation
Entero Healthcare Solutions Limited has received official confirmation from the Ministry of Corporate Affairs regarding the amalgamation of two of its subsidiary entities. The merger involves Chethana Pharma Distributors Private Limited and CPD Pharma Private Limited being integrated into Rada Medisolutions Private Limited via a fast-track route. This restructuring was formally sanctioned on April 17, 2026, with the effective date of the scheme set retrospectively as April 15, 2025.
Rationale Behind the Amalgamation
The primary objective of this corporate restructuring is to achieve a more streamlined group structure. By eliminating redundant entities with similar business objectives, the company anticipates several operational benefits, including:
- Operational Efficiency: Reduction in managerial overlaps and improved supervision of group business.
- Cost Optimization: Economies of scale and a significant reduction in administrative overheads and compliance costs.
- Resource Management: More productive utilization of assets and human resources across the unified entity.
Impact on Group Structure
Following the effectiveness of the scheme, the transferor companies—Chethana Pharma Distributors and CPD Pharma—will stand dissolved without the requirement of a formal winding-up process. As the entire equity share capital of the transferor entities was already held by the transferee company (Rada Medisolutions), no new shares will be issued. This consolidation reflects Entero Healthcare’s commitment to simplifying its legal framework and focusing on long-term, sustainable growth in the pharmaceutical distribution sector.
Source: BSE
